Angptl4 links α-cell proliferation following glucagon receptor inhibition with adipose tissue triglyceride metabolism

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 50, 2015, Pages 15498-15503

  Ben Zvi, Danny ^a   Barrandon, Ornella ^a   Hadley, Stephanie ^a   Blum, Barak ^a,b   Peterson, Quinn P ^a   Melton, Douglas A ^a  

^a Harvard University   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Angiopoietin; Diabetes; Glucagon; LPL; Metabolism

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE 4; GLUCAGON RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANGPTL4 PROTEIN, MOUSE; GLUCAGON;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALORIC RESTRICTION; CELL PROLIFERATION; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HYPERGLUCAGONEMIA; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PANCREAS ISLET ALPHA CELL; PLASMA; PRIORITY JOURNAL; SUPPLEMENTATION; UPREGULATION; WHITE ADIPOSE TISSUE; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CYTOLOGY; GENE EXPRESSION REGULATION; METABOLISM; SCID MOUSE;

ADIPOSE TISSUE; ANGIOPOIETINS; ANIMALS; CALORIC RESTRICTION; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GLUCAGON; GLUCAGON-SECRETING CELLS; MICE, INBRED C57BL; MICE, SCID; PPAR GAMMA; RECEPTORS, GLUCAGON; TRIGLYCERIDES;

EID: 84950336067     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1513872112     Document Type: Article

References (69)

1. Shah P, et al. (2000) Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85(11):4053-4059.
2. Chuang LT, et al. (2012) Comparison of the fatty acid composition of the serum phospholipids of controls, prediabetics and adults with type 2 diabetes. J Diabetes Mellitus 2(4):393-401.
3. Unger RH, Roth MG (2015) A new biology of diabetes revealed by leptin. Cell Metab 21(1):15-20.
4. D'Alessio D (2011) The role of dysregulated glucagon secretion in type 2 diabetes. Diabetes Obes Metab 13(Suppl 1):126-132.
5. Yoon KH, et al. (2003) Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 88(5):2300-2308.
6. Rahier J, Goebbels RM, Henquin JC (1983) Cellular composition of the human diabetic pancreas. Diabetologia 24(5):366-371.
7. Deng S, et al. (2004) Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes 53(3):624-632.
8. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH (2011) Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 60(2):391-397.
9. Lee Y, et al. (2012) Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc Natl Acad Sci USA 109(37):14972-14976.
10. Unger RH, Cherrington AD (2012) Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. J Clin Invest 122(1):4-12.
11. Lund A, Bagger JI, Christensen M, Knop FK, Vilsbøll T (2014) Glucagon and type 2 diabetes: The return of the alpha cell. Curr Diab Rep 14(12):555.
12. Kawamori D, et al. (2009) Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab 9(4):350-361.
13. van Dongen MG, et al. (2014) First proof of pharmacology in humans of a novel glucagon receptor antisense drug. J Clin Pharmacol 55 (3).
14. McShane LM, Franklin ZJ, O'Harte FP, Irwin N (2014) Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice. Peptides 60:95-101.
15. Mu J, et al. (2012) Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist. PLoS One 7(11):e49572.
16. Gelling RW, et al. (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 100(3):1438-1443.
17. Zhou C, Dhall D, Nissen NN, Chen CR, Yu R (2009) Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas 38(8):941-946.
18. Thorel F, et al. (2011) Normal glucagon signaling and β-cell function after near-total α-cell ablation in adult mice. Diabetes 60(11):2872-2882.
19. Dadon D, et al. (2012) Glucose metabolism: Key endogenous regulator of β-cell replication and survival. Diabetes Obes Metab 14(Suppl 3):101-108.
20. Sharma RB, et al. (2015) Insulin demand regulates β cell number via the unfolded protein response. J Clin Invest 125(10):3831-3846.
21. Solloway MJ, et al. (2015) Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of α-cell mass. Cell Rep 12(3):495-510.
22. Zhu P, Goh YY, Chin HF, Kersten S, Tan NS (2012) Angiopoietin-like 4: A decade of research. Biosci Rep 32(3):211-219.
23. Sukonina V, Lookene A, Olivecrona T, Olivecrona G (2006) Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc Natl Acad Sci USA 103(46):17450-17455.
24. Mandard S, et al. (2004) The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem 279(33):34411-34420.
25. Koliwad SK, et al. (2009) Angiopoietin-like 4(ANGPTL4, fasting-induced adipose factor) is a direct glucocorticoid receptor target and participates in glucocorticoidregulated triglyceride metabolism. J Biol Chem 284(38):25593-25601.
26. Kersten S, et al. (2000) Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 275(37):28488-28493.
27. Catoire M, et al. (2014) Fatty acid-inducible ANGPTL4 governs lipid metabolic response to exercise. Proc Natl Acad Sci USA 111(11):E1043-E1052.
28. Yu X, et al. (2005) Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. Proc Natl Acad Sci USA 102(5):1767-1772.
29. Kersten S, et al. (2009) Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler Thromb Vasc Biol 29(6):969-974.
30. Dijk W, et al. (2015) ANGPTL4 mediates shuttling of lipid fuel to brown adipose tissue during sustained cold exposure. eLife 4:4.
31. Köster A, et al. (2005) Transgenic angiopoietin-like (angptl) 4 overexpression and targeted disruption of angptl4 and angptl3: Regulation of triglyceride metabolism. Endocrinology 146(11):4943-4950.
32. Romeo S, et al. (2009) Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest 119(1):70-79.
33. Post SR, Rubinstein PG, Tager HS (1993) Mechanism of action of des-His1-[Glu9]glucagon amide, a peptide antagonist of the glucagon receptor system. Proc Natl Acad Sci USA 90(5):1662-1666.
34. Unson CG, Gurzenda EM, Merrifield RB (1989) Biological activities of des-His1[Glu9] glucagon amide, a glucagon antagonist. Peptides 10(6):1171-1177.
35. Grigoryan M, Kedees MH, Charron MJ, Guz Y, Teitelman G (2012) Regulation of mouse intestinal L cell progenitors proliferation by the glucagon family of peptides. Endocrinology 153(7):3076-3088.
36. Ellingsgaard H, et al. (2008) Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci USA 105(35):13163-13168.
37. Cai Y, et al. (2014) IL-6-dependent proliferation of alpha cells in mice with partial pancreatic-duct ligation. Diabetologia 57(7):1420-1427.
38. Longuet C, et al. (2008) The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab 8(5):359-371.
39. Yang J, et al. (2011) Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: Implications on anti-glucagon therapies for diabetes. BMC Genomics 12:281.
40. Binder JX, et al. (2014) COMPARTMENTS: Unification and visualization of protein subcellular localization evidence. Database (Oxford) 2014: bau012.
41. Yi P, Park JS, Melton DA (2013) Betatrophin: A hormone that controls pancreatic β cell proliferation. Cell 153(4):747-758.
42. Finegood DT, Scaglia L, Bonner-Weir S (1995) Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes 44(3):249-256.
43. Teta M, Long SY, Wartschow LM, Rankin MM, Kushner JA (2005) Very slow turnover of beta-cells in aged adult mice. Diabetes 54(9):2557-2567.
44. Brelje TC, Bhagroo NV, Stout LE, Sorenson RL (2008) Beneficial effects of lipids and prolactin on insulin secretion and beta-cell proliferation: A role for lipids in the adaptation of islets to pregnancy. J Endocrinol 197(2):265-276.
45. Bäckhed F, et al. (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 101(44):15718-15723.
46. Lichtenstein L, et al. (2010) Angptl4 protects against severe proinflammatory effects of saturated fat by inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab 12(6):580-592.
47. Stolovich-Rain M, Hija A, Grimsby J, Glaser B, Dor Y (2012) Pancreatic beta cells in very old mice retain capacity for compensatory proliferation. J Biol Chem 287(33):27407-27414.
48. Sturis J, et al. (2003) GLP-1 derivative liraglutide in rats with beta-cell deficiencies: Influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 140(1):123-132.
49. Yi P, Park JS, Melton DA (2014) Perspectives on the activities of ANGPTL8/betatrophin. Cell 159(3):467-468.
50. Spaeth JM, et al. (2015) The FOXP1, FOXP2 and FOXP4 transcription factors are required for islet alpha cell proliferation and function in mice. Diabetologia 58(8):1836-1844.
51. Liu Z, et al. (2011) Insulin and glucagon regulate pancreatic α-cell proliferation. PLoS One 6(1):e16096.
52. Xu A, et al. (2005) Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci USA 102(17):6086-6091.
53. Gray NE, et al. (2012) Angiopoietin-like 4(Angptl4) protein is a physiological mediator of intracellular lipolysis in murine adipocytes. J Biol Chem 287(11):8444-8456.
54. Longuet C, et al. (2013) Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: Evidence for a circulating α-cell growth factor. Diabetes 62(4):1196-1205.
55. Galic S, Oakhill JS, Steinberg GR (2010) Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316(2):129-139.
56. Charron MJ, Vuguin PM (2015) Lack of glucagon receptor signaling and its implications beyond glucose homeostasis. J Endocrinol 224(3):R123-R130.
57. Chen J, et al. (2015) In vivo targeted delivery of ANGPTL8 gene for beta cell regeneration in rats. Diabetologia 58(5):1036-1044.
58. Gusarova V, et al. (2014) ANGPTL8/betatrophin does not control pancreatic beta cell expansion. Cell 159(3):691-696.
59. Wang Y, et al. (2013) Mice lacking ANGPTL8(Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci USA 110(40):16109-16114.
60. Cox AR, et al. (2015) Angiopoietin-like protein 8(ANGPTL8)/betatrophin overexpression does not increase beta cell proliferation in mice. Diabetologia 58(7):1523-1531.
61. Zhang R (2012) Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun 424(4):786-792.
62. Ren G, Kim JY, Smas CM (2012) Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab 303(3):E334-E351.
63. Mattijssen F, Kersten S (2012) Regulation of triglyceride metabolism by Angiopoietinlike proteins. Biochim Biophys Acta 1821(5):782-789.
64. Yoshida K, Shimizugawa T, Ono M, Furukawa H (2002) Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J Lipid Res 43(11):1770-1772.
65. Yau MH, et al. (2009) A highly conserved motif within the NH2-terminal coiled-coil domain of angiopoietin-like protein 4 confers its inhibitory effects on lipoprotein lipase by disrupting the enzyme dimerization. J Biol Chem 284(18):11942-11952.
66. Pascoe J, et al. (2012) Free fatty acids block glucose-induced β-cell proliferation in mice by inducing cell cycle inhibitors p16 and p18. Diabetes 61(3):632-641.
67. Charles MA, et al. (1997) The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: Results of the Paris Prospective Study. Diabetologia 40(9):1101-1106.
68. Chen H, et al. (1996) Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice. Cell 84(3):491-495.
69. Blum B, et al. (2014) Reversal of β cell de-differentiation by a small molecule inhibitor of the TGFβ pathway. eLife 3:e02809.